We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

14 hedge funds and large institutions have $1.42M invested in Moleculin Biotech in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

40% more funds holding

Funds holding: 10 → 14 (+4)

0% more ownership

Funds ownership: 0% → 0% (+0%)

9% less capital invested

Capital invested by funds: $1.56M → $1.42M (-$140K)

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$64.9K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$51.9K
3
LNWWM
Laird Norton Wetherby Wealth Management
California
+$38.9K
4
VF
Virtu Financial
New York
+$26K
5
TSS
Two Sigma Securities
New York
+$21.6K

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$29K
2
NFG
Next Financial Group
Texas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$855K +$64.9K +15 +8%
Truist Financial
2
Truist Financial
North Carolina
$167K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$159K +$51.9K +12 +46%
Bank of America
4
Bank of America
North Carolina
$47K – – –
LNWWM
5
Laird Norton Wetherby Wealth Management
California
$37K +$38.9K +9 New
Commonwealth Equity Services
6
Commonwealth Equity Services
Massachusetts
$29K +$4.33K +1 +17%
VF
7
Virtu Financial
New York
$26K +$26K +6 New
Northern Trust
8
Northern Trust
Illinois
$25K +$4.33K +1 +20%
Morgan Stanley
9
Morgan Stanley
New York
$23K – – –
TSS
10
Two Sigma Securities
New York
$21K +$21.6K +5 New
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$15K +$13K +3 New
Deutsche Bank
12
Deutsche Bank
Germany
$7K +$4.33K +1 +100%
OIA
13
OneDigital Investment Advisors
Kansas
$5K +$4.33K +1 New
UBS Group
14
UBS Group
Switzerland
$4K – – –
GRP
15
Global Retirement Partners
California
$1K – – –
CS
16
Credit Suisse
Switzerland
– -$29K -5 Closed
NFG
17
Next Financial Group
Texas
– -$1K – –

MBRX Hedge Fund Activity: Q4 2017 in Review

14 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2017, worth a combined $1.42M — down 9% from $1.56M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MBRX positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $64.9K. The largest seller was Credit Suisse, exiting entirely with an estimated $29K sold.

  • 14 institutional investors held Moleculin Biotech (MBRX) as of Q4 2017, up from 10 in Q3 2017.
  • Funds reported $1.42M of Moleculin Biotech stock for Q4 2017, down 9% quarter-over-quarter.
  • 5 funds opened new Moleculin Biotech positions in Q4 2017 and 1 closed out, a net change of +4 holders.
  • The largest Moleculin Biotech buyer in Q4 2017 was Vanguard Group, an estimated $64.9K added.
  • The largest Moleculin Biotech seller in Q4 2017 was Credit Suisse, an estimated $29K sold.

Based on aggregated 13F filings for Q4 2017.